Ramucirumab for metastatic gastric or gastroesophageal junction cancer: Results and implications of the REGARD trial

Future Oncology

Volumn 10, Issue 9, 2014, Pages 1549-1557

  Liguigli, Wanda ^a   Tomasello, Gianluca ^a   Toppo, Laura ^a   Ratti, Margherita ^a   Passalacqua, Rodolfo ^a  

^a Oncology Division   (Italy)

Author keywords

gastric cancer; ramucirumab; REGARD

Indexed keywords

RAMUCIRUMAB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; ESOPHAGUS CANCER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; INTESTINE PERFORATION; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; ADENOCARCINOMA; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LOWER ESOPHAGUS SPHINCTER; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PERITONEAL NEOPLASMS; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; ESOPHAGOGASTRIC JUNCTION; HUMANS; KAPLAN-MEIER ESTIMATE; PERITONEAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84906537605     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.106     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011
2. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 17(3), CD004064 (2010
3. Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer 17(2), 213-225 (2014
4. Cervantes A, Roda D, Tarazona N, Rosellò S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat. Rev. 39(1), 60-67 (2013
5. Kang JH, Lee SI, Lim do H et al. Salvage chemotherapy for pretreated gastric cancer: a randomized Phase Iii trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 30(13), 1513-1518 (2012
6. Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-A randomised Phase Iii study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer. 47(15), 2306-2314 (2011
7. Ford HE, Marshall A, Bridgewater JA et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, Phase 3 randomised controlled trial. Lancet Oncol. 15(1), 78-86 (2014
8. Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 10(9), 903-912 (2009
9. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010
10. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled Phase Iii study. J. Clin. Oncol. 29(30), 3968-3976 (2011
11. Cho JY. Molecular diagnosis for personalized target therapy in gastric cancer. J. Gastric Cancer 13(3), 129-135 (2013
12. Meza-Junco J, Sawyer MB. Metastatic gastric cancer-focus on targeted therapies. Biologics 6, 137-146 (2012
13. Ohtsu A, Ajani JA, Bai YX et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, Phase Iii GRANITE-1 study. J. Clin. Oncol. 31(31), 3935-3943 (2013
14. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophagel junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, Phase 3 trial. Lancet 383(9911), 31-39 (2014
15. Scartozzi M, Giampieri R, Loretelli C et al. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics 14(16), 1991-1998 (2013
16. Peng L, Zhan P, Zhou Y et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol. Biol. Rep. 39(10), 9473-9484 (2012
17. Spratlin J. Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelian growth factor receptor-2. Curr. Oncol. Rep. 13, 97-102 (2011
18. Franklin MC, Navarro EC, Wang Y et al. The structural basis for the function of two anti-VEGF receptor 2 antibodies. Structure 19, 1097-1107 (2011
19. Spratlin JL, Cohen RB, Eadens M et al. PhaseI pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28(5), 780-787 (2010
20. Saif MW. Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag. Res. 5, 103-115 (2013
21. Wilke H, Van Cutsem E. RAINBOW: a global, Phase Iii, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum-and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). Presented at: 2014 Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 16-18 January 2014
22. Eli Lilly and Company. A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer. http://clinicaltrials.gov/ show/NCT01246960
23. Eli Lilly and Company. Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes. http://clinicaltrials.gov/show/NCT01017731
24. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events version 4.0. http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm#ct-40
25. Ilson DH. Angiogenesis in gastric cancer: hitting the target? Lancet 383(9911), 4-6 (2014
26. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomized open label Phase 3 trial. Lancet Oncol. 14, 490-499 (2013
27. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin and capecitabine with or without panitunumab for patients with previously untreated esophagogastric cancer (REAL-3): a randomized open label Phase 3 trial. Lancet Oncol. 14, 481-489 (2013
28. Van Cutsem E, de Haas S, Kang YK et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized Phase Iii trial. J. Clin. Oncol. 30(17), 2119-2127 (2012
29. Janjigian YY, Kelsen DP. Genomic dysregulation in gastric tumors. J. Surg. Oncol. 107(3), 237-242 (2013).